Liferay Portal/DXP Export permission

CVSS Meta Temp Score
CVSS is a standardized scoring system to determine possibilities of attacks. The Temp Score considers temporal factors like disclosure, exploit and countermeasures. The unique Meta Score calculates the average score of different sources to provide a normalized scoring system.
Current Exploit Price (≈)
Our analysts are monitoring exploit markets and are in contact with vulnerability brokers. The range indicates the observed or calculated exploit price to be seen on exploit markets. A good indicator to understand the monetary effort required for and the popularity of an attack.
CTI Interest Score
Our Cyber Threat Intelligence team is monitoring different web sites, mailing lists, exploit markets and social media networks. The CTI Interest Score identifies the interest of attackers and the security community for this specific vulnerability in real-time. A high score indicates an elevated risk to be targeted for this vulnerability.
5.0$0-$5k0.00

Summaryinfo

A vulnerability categorized as critical has been discovered in Liferay Portal and DXP. Impacted is an unknown function of the component Export. The manipulation results in permission. This vulnerability is known as CVE-2022-38512. No exploit is available.

Detailsinfo

A vulnerability, which was classified as problematic, was found in Liferay Portal and DXP (affected version unknown). Affected is an unknown functionality of the component Export. The manipulation with an unknown input leads to a permission vulnerability. CWE is classifying the issue as CWE-275. This is going to have an impact on confidentiality. CVE summarizes:

The Translation module in Liferay Portal v7.4.3.12 through v7.4.3.36, and Liferay DXP 7.4 update 8 through 36 does not check permissions before allowing a user to export a web content for translation, allowing attackers to download a web content page's XLIFF translation file via crafted URL.

The weakness was published 09/22/2022. The advisory is shared for download at portal.liferay.dev. This vulnerability is traded as CVE-2022-38512 since 08/22/2022. There are neither technical details nor an exploit publicly available. The MITRE ATT&CK project declares the attack technique as T1222.

There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.

VulDB is the best source for vulnerability data and more expert information about this specific topic.

Productinfo

Type

Vendor

Name

License

CPE 2.3info

CPE 2.2info

CVSSv4info

VulDB Vector: 🔍
VulDB Reliability: 🔍

CVSSv3info

VulDB Meta Base Score: 5.0
VulDB Meta Temp Score: 5.0

VulDB Base Score: 3.5
VulDB Temp Score: 3.5
VulDB Vector: 🔍
VulDB Reliability: 🔍

NVD Base Score: 6.5
NVD Vector: 🔍

CVSSv2info

AVACAuCIA
💳💳💳💳💳💳
💳💳💳💳💳💳
💳💳💳💳💳💳
VectorComplexityAuthenticationConfidentialityIntegrityAvailability
UnlockUnlockUnlockUnlockUnlockUnlock
UnlockUnlockUnlockUnlockUnlockUnlock
UnlockUnlockUnlockUnlockUnlockUnlock

VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍

Exploitinginfo

Class: Permission
CWE: CWE-275 / CWE-266
CAPEC: 🔍
ATT&CK: 🔍

Physical: No
Local: No
Remote: Yes

Availability: 🔍
Status: Not defined

EPSS Score: 🔍
EPSS Percentile: 🔍

Price Prediction: 🔍
Current Price Estimation: 🔍

0-DayUnlockUnlockUnlockUnlock
TodayUnlockUnlockUnlockUnlock

Threat Intelligenceinfo

Interest: 🔍
Active Actors: 🔍
Active APT Groups: 🔍

Countermeasuresinfo

Recommended: no mitigation known
Status: 🔍

0-Day Time: 🔍

Timelineinfo

08/22/2022 🔍
09/22/2022 +31 days 🔍
09/22/2022 +0 days 🔍
05/28/2025 +978 days 🔍

Sourcesinfo

Advisory: portal.liferay.dev
Status: Confirmed

CVE: CVE-2022-38512 (🔍)
GCVE (CVE): GCVE-0-2022-38512
GCVE (VulDB): GCVE-100-209280

Entryinfo

Created: 09/22/2022 08:00
Updated: 05/28/2025 00:15
Changes: 09/22/2022 08:00 (37), 10/22/2022 09:14 (11), 05/28/2025 00:15 (16)
Complete: 🔍
Cache ID: 216::103

VulDB is the best source for vulnerability data and more expert information about this specific topic.

Discussion

No comments yet. Languages: en.

Please log in to comment.

◂ PreviousOverviewNext ▸

Do you need the next level of professionalism?

Upgrade your account now!